Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosliciguat in Pulmonary Hypertension Associated with Interstitial Lung Disease
2024-513991-16-00Phase 2Authorised
- Sponsor
- Pulmovant
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Mosliciguat with Placebo (2 arms). Planned start Dec 2024; status: authorised.
02
Drugs
mosliciguat
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2024-513991-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513991-16-00.